Expand COGT Menu
COGT MENU

COGT Latest Press Releases

-- June 12, 2026 --

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress Globe Newswire 8:01 AM
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress Globe Newswire 8:00 AM

-- May 30, 2026 --

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 8:00 AM

-- May 28, 2026 --

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST Globe Newswire 8:00 AM

-- May 27, 2026 --

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference Globe Newswire 8:00 AM

-- May 12, 2026 --

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress Globe Newswire 9:30 AM

-- May 5, 2026 --

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- April 21, 2026 --

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Globe Newswire 8:00 AM

-- April 17, 2026 --

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 8:00 AM

-- April 1, 2026 --

Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) Globe Newswire 8:00 AM

-- March 16, 2026 --

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) Globe Newswire 8:00 AM

-- February 28, 2026 --

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting Globe Newswire 9:45 AM

-- February 17, 2026 --

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 8:00 AM

-- February 10, 2026 --

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting Globe Newswire 8:00 AM

-- January 26, 2026 --

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST) Globe Newswire 8:00 AM

-- January 20, 2026 --

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes